Page 123 - 2020_02-Haematologica-web

Clinical features of Rosai-Dorfman disease
inhibitors, the ongoing study of cobimetinib in histiocytic disorders (NCT02649972), which includes RDD, will hopefully provide the first FDA approved treatment for this disease.37
Acknowledgments
Thisstudywaspartlypresentedatthe2017AmericanSociety of Hematology conference, Atlanta, GA, USA.
References
1. Destombes P. [Adenitis with lipid excess, in children or young adults, seen in the Antilles and in Mali. (4 cases)]. Bull Soc Pathol Exot Filiales. 1965;58(6):1169-1175.
2. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological enti- ty. Arch Pathol. 1969;87(1):63-70.
3. Foucar E, Rosai J, Dorfman R. Sinus histiocy- tosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the enti- ty. Semin Diagn Pathol. 1990;7(1):19-73.
4. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919- 1923.
5. Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154-165.
6. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700-2703.
7. Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman dis- ease. Mod Pathol. 2017;30(10):1367-1377.
8. Chan JKC PS, Fletcher CDM, Weiss LM, Grogg KL. Follicular dendritic cell sarcoma. In: Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Theile J. , ed. WHO Classification of tumours of haematopoietic and lymphoid tissues: IARC; 2017:476-479.
9. Chan JKC PS, Delsol G, Fletcher CDM, Weiss LM, Grogg KL. Follicular dendritic cell sarcoma. In: Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Theile J, Vardiman JW, ed. WHO Classification of tumours of haematopoietic and lymphoid tissues: IARC; 2008:363-364.
10. Ravindran A, Goyal G, Failing JJ, Go RS, Rech KL. Florid dermatopathic lymphadenopathyA morphological mimic of Langerhans cell histiocytosis. Clin Case Rep. 2018;6(8):1637-1638.
11. Beaubier N, Tell R, Huether R, et al. Clinical validation of the Tempus xO assay. Oncotarget. 2018;9(40):25826-25832.
12. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on mas- sively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-1031.
13. Lanman RB, Mortimer SA, Zill OA, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating
tumor DNA. PLoS One. 2015; 10(10):
e0140712.
14. Young JR, Johnson GB, Murphy RC, Go RS,
Broski SM. (18)F-FDG PET/CT in Erdheim- Chester disease: imaging findings and potential BRAF mutation biomarker. J Nucl Med. 2018;59(5):774-779.
15. Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diag- nosis and clinical management of Rosai- Dorfman-Destombes disease. Blood. 2018; 131(26):2877-2890.
16. Goyal G, Shah MV, Call TG, Litzow MR, Hogan WJ, Go RS. Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease. JAMA Oncol. 2017; 3(9):1253-1256.
26. Al-Khateeb TH. Cutaneous Rosai-Dorfman Disease of the face: a comprehensive litera- ture review and case report. J Oral Maxillofac Surg. 2016;74(3):528-540.
27. Forest F, N'Guyen A T, Fesselet J, et al. Meningeal Rosai-Dorfman disease mimick- ing meningioma. Ann Hematol. 2014;93 (6):937-940.
28. Aouba A, Terrier B, Vasiliu V, et al. Dramatic clinical efficacy of cladribine in Rosai- Dorfman disease and evolution of the cytokine profile: towards a new therapeutic approach. Haematologica. 2006;91(12 Suppl):ECR52.
29. Konca C, Ozkurt ZN, Deger M, Aki Z, Yagci M. Extranodal multifocal Rosai-Dorfman disease: response to 2-chlorodeoxyadeno- sine treatment. Int J Hematol. 2009;89(1):58-
17. Purysko AS, Westphalen AC, Remer EM,
Coppa CP, Leao Filho HM, Herts BR. 62.
Imaging manifestations of hematologic diseases with renal and perinephric involvement. Radiographics. 2016; 36(4): 1038-1054.
30. Horneff G, Jurgens H, Hort W, Karitzky D, Gobel U. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to methotrexate and mercaptop- urine. Med Pediatr Oncol. 1996;27(3):187-
18. Ozkaya N, Rosenblum MK, Durham BH, et
al. The histopathology of Erdheim-Chester 192.
disease: a comprehensive review of a mole- cularly characterized cohort. Mod Pathol. 2018;31(4):581-597.
19. Paulli M, Bergamaschi G, Tonon L, et al. Evidence for a polyclonal nature of the cell Infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman Disease). Br J Haematol. 1995;91(2):415-418.
20. Matter MS, Bihl M, Juskevicius D, Tzankov A. Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman dis- ease. Virchows Archiv. 2017;471(4):545-547.
21. Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A. Rosai-Dorfman dis- ease harboring an activating KRAS K117N missense mutation. Head Neck Pathol. 2016; 10(3):394-399.
22. Goyal G, Lau D, Nagle AM, et al. Tumor mutational burden and other predictive immunotherapy markers in histiocytic neo- plasms. Blood. 2019;133(14):1607-1610.
23. Litzner BR, Subtil A, Vidal CI. Combined cutaneous Rosai-Dorfman disease and local- ized cutaneous Langerhans cell histiocytosis within a single subcutaneous nodule. Am J Dermatopathol. 2015;37(12):936-939.
24. Lima FB, Barcelos PS, Constancio AP, Nogueira CD, Melo-Filho AA. Rosai- Dorfman disease with spontaneous resolu- tion: case report of a child. Rev Bras Hematol Hemoter. 2011;33(4):312-314.
25. Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with mas- sive lymphadenopathy (Rosai-Dorfman dis- ease): report of a case and literature review. Am J Hematol. 2002;69(1):67-71.
31. Maklad AM, Bayoumi Y, Tunio M, Alshakweer W, Dahar MA, Akbar SA. Steroid-resistant extranodal Rosai-Dorfman disease of cheek mass and ptosis treated with radiation therapy. Case Rep Hematol. 2013;2013:428297.
32. Petschner F, Walker UA, Schmitt-Graff A, Uhl M, Peter HH. ["Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab]. Dtsch Med Wochenschr. 2001;126(37):998-1001.
33. Jabali Y, Smrcka V, Pradna J. Rosai-Dorfman disease: successful long-term results by com- bination chemotherapy with prednisone, 6- mercaptopurine, methotrexate, and vinblas- tine: a case report. Int J Surg Pathol. 2005;13(3):285-289.
34. Scheel MM, Rady PL, Tyring SK, Pandya AG. Sinus histiocytosis with massive lym- phadenopathy: presentation as giant granu- loma annulare and detection of human her- pesvirus 6. J Am Acad Dermatol. 1997;37(4):643-646.
35. Toguri D, Louie AV, Rizkalla K, Franklin J, Rodrigues G, Venkatesan V. Radiotherapy for steroid-resistant laryngeal Rosai- Dorfman disease. Curr Oncol. 2011;18(3): e158-162.
36. Paryani NN, Daugherty LC, O'Connor MI, Jiang L. Extranodal rosai-dorfman disease of the bone treated with surgery and radiother- apy. Rare Tumors. 2014;6(4):5531.
37. Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019; 567(7749):521-524.
haematologica | 2020; 105(2)
357